A pharmacy that fills a prescription exactly as written can still face a recoupment demand if the prescriber turns out to be on the federal exclusion list, on the CMS preclusion list, or dead before the claim was ever submitted. PBMs build that screening into routine claims processing, and a hit on any of the three grounds becomes a PBM audit finding once the claim is already paid, with recoupment on the flagged claim, extrapolation across the lookback period, and network termination risk if the pattern repeats.
How PBMs Screen Claims Against Federal Exclusion and Preclusion Lists
The Office of Inspector General maintains the List of Excluded Individuals and Entities (LEIE) under section 1128 of the Social Security Act. Mandatory exclusion follows specific convictions, including felony convictions for the unlawful manufacture, distribution, prescription, or dispensing of controlled substances. The payment bar reaches further than the excluded person's own billing: items and services furnished on the prescription of an excluded person are not payable once the pharmacy knows or should know of the exclusion. That wording turns a pharmacy's claim into a finding when the pharmacy knew, or should have known, that the drug it dispensed was prescribed by someone on the list, even though the pharmacy never billed under the excluded prescriber's own name. Judi Rx (formerly Capital Rx) and the national PBMs build that same exclusion check into claims processing, because OIG has told providers they should confirm, at the point of service, that the prescriber is not excluded. This is why a prescriber sanction can surface as a claims-processing rejection before it becomes an audit letter.
The CMS Preclusion List and the Point-of-Sale Rejection
The CMS preclusion list is a separate federal list, built for Medicare Advantage and Part D specifically. CMS places a prescriber on it when the prescriber is already revoked from Medicare under a reenrollment bar CMS has found detrimental to the program, or when the prescriber has a felony conviction within the preceding ten years that CMS deems detrimental, and mails a letter naming the reason and the applicable appeal rights before the prescriber's name is added to the published list. Since April 1, 2019, Part D sponsors must reject a pharmacy's claim at the point of sale, not only on later audit, when the claim names a prescriber on the list. That rejection only reaches claims submitted on or after the effective date, so a prescription written and billed before the prescriber's name was added is not one a preclusion-based finding should reach.
When the Prescriber Is Deceased
A prescriber's death deactivates the prescriber's National Provider Identifier in NPPES, the federal provider registry, and NPPES assigns that deactivation its own reason code, DT, for death. The record does not update itself. Federal regulation requires a covered health care provider to report any change in its NPS data within 30 days of the change (45 CFR 162.410(a)(4)), but that duty assumes the provider is the one reporting. After a death, whoever notifies CMS, an estate, a former employer, or a licensing board, works from whatever paperwork reaches them, so a finding built on this ground, which compares the date of service to the deactivation date on file, can rest on a date that lags the actual date of death.
Curing or Contesting the Finding
Every one of these findings turns on a date, and the date is the first thing to check. OIG exclusions, CMS preclusion-list entries, and NPPES deactivations each carry their own effective date, and the payment bar runs forward from it, not back against a prescription written and billed before the sanction took effect. The second check is identity: a shared name, a transposed NPI, or a stale NPPES address can produce a false hit against the wrong person, so pulling the prescriber's actual NPI off the claim and checking it directly against the LEIE and the preclusion list matters more than trusting the PBM's own match. When neither defense holds, the dispute moves into the PBM's own audit appeal, where the strongest remaining argument is usually the extrapolation applied across the lookback period, not the flagged claim itself. An unresolved finding does not stay contained to the current audit. It resurfaces in the due diligence of a pharmacy sale, and compounds the longer it goes unanswered.
Items and services furnished on the prescription of an excluded person are not payable once the pharmacy knows, or should know, that the prescriber is excluded, so the safer course is to check a new prescriber's name against the LEIE before the claim is submitted, not after a recoupment letter arrives.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's PBM audit defense attorneys represent pharmacies nationwide against audit findings built on excluded, precluded, or deceased prescribers, from the first screening flag through the PBM's own appeal process. If a PBM has tied a recoupment demand to a prescriber sanction, contact Health Law Alliance's attorneys for a free, confidential consultation.
